Business Context and Reporting Period
This Form 8-K filing by Palisade Bio, Inc. (PALI) reports on shareholder votes conducted during two special meetings held on October 4, 2022, and October 6, 2022. The report was filed on October 7, 2022.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure actions. It does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Shareholder Actions
October 4, 2022 Special Meeting
- Reverse Stock Split Authorization: Shareholders approved an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-10 and 1-for-50. The Board of Directors retains discretion to set the exact ratio and timing before the 2023 annual meeting.
- Voting Results: Of 71,240,169 shares outstanding, 48,164,475 were represented. The proposal passed with 45,212,808 votes for, 2,933,201 against, and 18,466 abstentions.
October 6, 2022 Special Meeting
- Warrant Issuance Approval: Shareholders approved the issuance of up to 110,400,000 shares of common stock upon the exercise of Series 1 and Series 2 warrants issued in the August 2022 underwritten offering. This issuance could exceed 20% of the pre-offering outstanding shares, requiring shareholder approval under NASDAQ Listing Rule 5635(d).
- Authorized Share Reduction: Shareholders approved decreasing the number of authorized common shares from 300,000,000 to 280,000,000.
- Voting Results: Of 21,880,169 shares outstanding, 12,642,168 were represented.
- Warrant Proposal: 5,488,362 votes for, 4,042,423 against, 11,044 abstentions, and 3,100,339 non-votes.
- Authorized Share Reduction: 11,466,286 votes for, 1,162,410 against, and 13,472 abstentions.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the context of the shareholder votes. The primary contingency noted is the Board's future discretion to execute the reverse stock split within the approved parameters.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio and effective date once announced by the Board of Directors.
- Monitor the exercise status of the Series 1 and Series 2 warrants to assess potential dilution from the approved 110,400,000 shares.
- Confirm the updated authorized share count of 280,000,000 in subsequent filings.
- Note the significant number of non-votes (3,100,339) on the warrant issuance proposal, indicating broker non-votes or withheld votes.